4D Molecular Therapeutics FDMT Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's additional paid-in capital?
- 4D Molecular Therapeutics (FDMT) reported additional paid-in capital of $1.24B in Q1 2026.
- How has 4D Molecular Therapeutics's additional paid-in capital changed year-over-year?
- 4D Molecular Therapeutics's additional paid-in capital increased by 13.1% year-over-year, from $1.09B to $1.24B.
- What is the long-term trend for 4D Molecular Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's additional paid-in capital has grown at a 25.5% compound annual growth rate (CAGR), from $392.06M to $1.22B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.